Search Results

On Saturday, May 16, approximately 110 people, including neuroendocrine cancer patients, caregivers, clinicians, scientists, advocates, and industry partners, gathered in Atlanta, Georgia, for the Neuroendocrine Cancer Foundation Patient Education Event. Designed specifically for individuals living with neuroendocrine cancer (or NET) and their loved ones, this full-day program brought together leading regional experts from Emory University, the University of Alabama at Birmingham (UAB), and Vanderbilt University Medical Center to provide practical, up-to-date education on the diagnosis and management of neuroendocrine cancer. Attendees traveled from across the Southeast and beyond to learn more about their disease, connect with others who understand the NET journey, and gain hope through education and community. For many, this was their very first NET patient education event. Notably, none of the attendees had previously participated in clinical trials or research, underscoring the importance of continuing efforts to improve patient education and awareness around emerging treatment opportunities. Participants remained highly engaged throughout the day, asking thoughtful questions and sharing meaningful conversations with both experts and fellow attendees. Prior to the event, Dr. Daniel Halperin shared his thoughts on the value of attending in-person educational programs during this rapidly evolving time in neuroendocrine cancer care: The day opened with an inspiring patient story from Jay, who shared his experience living with neuroendocrine cancer and his perspective on learning to live “symbiotically” with the disease. He spoke candidly about refusing to let NET define or limit his life and about maintaining emotional steadiness even during moments of tumor progression or treatment changes. His honesty, humor, and optimism resonated deeply with attendees and helped set the tone for a patient-centered day grounded in resilience and hope. Eight outstanding speakers covered a broad range of clinical and practical topics, including surgery, liver-directed therapy, systemic treatments, imaging, PRRT, and clinical trials. Attendees also learned about emerging research exploring GLP-1 agents and neuroendocrine tumors from a leading scientist in the field. Event Recording To help attendees continue learning and revisit the information shared during the program, watch the full event recording below. To download speaker slides, click the link beneath each presentation title. Two Q&A panel discussions gave attendees the opportunity to ask questions spanning a wide range of topics, from preparing for a first NET appointment and navigating treatment decisions to understanding clinical trials and the growing role of artificial intelligence in research and clinical care. Welcome & Introductions A Patient Journey Multidisciplinary Approach to Surgery for NET Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Understanding Your Scans and PRRT: How Imaging Guides Treatment Preparing for PRRT: What Patients Need to Know Systemic Therapy for Neuroendocrine Cancer: What Patients Need to Know Q&A Session + Expert Panel #1 How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies? What It Means To Be Part of a Clinical Trial Clinical Trials: What's on the Horizon? Q&A Session + Expert Panel #2 Whether newly diagnosed or living with NET for more than 20 years, participants consistently shared that the information was practical, understandable, and highly relevant to their daily lives. Beyond the educational sessions, attendees valued the opportunity to connect personally with speakers, patient advocates, and industry supporters. Many especially enjoyed learning fun and humanizing facts about the clinicians’ hobbies and interests outside of medicine. Participants were also treated to a moving reading of healing poetry by Dr. Saima Muzahir, which brought an especially meaningful and reflective moment to the day. By the close of the program, attendees left with new knowledge, new connections, and renewed hope. The event highlighted not only the tremendous progress being made in neuroendocrine cancer research and treatment, but also the collective commitment across the NET community to help people live longer and better with this uncommon disease. The post-event survey, completed by approximately 15% of the attendees, highlighted the success of the conference: Conference Success Highlights 100% of respondents said the event was worthwhile 100% would recommend the conference to others 100% said they visited Supporter's Exhibit Tables 100% of the respondents said they have an increased knowledge of various procedures and/or treatments specific to my diagnosis. Attendees rated the event an average of 4.75 out of 5 overall More than 91% reported a better understanding of neuroendocrine cancer Participants rated their increased awareness of NCF resources at an average of 4.7 out of 5 Participants described the event as: “Terrific” “Very informative” “Helpful in understanding treatment options.” “A wonderful opportunity to connect with experts and other patients” Following the Neuroendocrine Cancer Foundation’s Patient Education Conference in Atlanta, Drs. Seth Concors and Udhay Grewal of Emory University discussed the value of multidisciplinary care for people living with neuroendocrine cancer. They highlighted how bringing multiple specialists together in a coordinated team approach helps patients better understand their options, streamline care, and develop comprehensive treatment plans closer to home. Special thanks to Dr. Udhayvir Grewal for his collaboration and partnership with the Neuroendocrine Cancer Foundation in making this event possible. To learn more about upcoming Neuroendocrine Cancer Foundation in-person and virtual programs, visit the NCF Upcoming Events & Meetings page. THANKS TO OUR SPONSORS

Recapping the SNMMI Neuroendocrine Cancer Patient Education Event On May 31st, the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Neuroendocrine Cancer Patient Education Day brought the NET community to the Los Angeles Convention Center, co-organized by the Neuroendocrine Cancer Foundation (NCF) and NorCal CarciNET's Josh Mailman alongside the SNMMI Annual Conference. Offered completely free and in a hybrid format, the event opened doors for patients and families, whether they attended in person or tuned in from home. From morning sessions on imaging and clinical trials to an afternoon deep dive into the frontiers of theranostics, the day was anchored by a throughline that never let up: the patient is at the center of all of it. This video is a recap of the Patient Education Day at SNMMI. Starting with the big picture: nuclear medicine and clinical trials The morning opened with a grounding overview of nuclear medicine and molecular imaging from Martin Tornai, PhD, of the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering. For many patients, terms like DOTATATE and PRRT carry enormous weight, and this session gave attendees a clearer foundation for understanding the tools being used in their care. George Fisher, MD, PhD, of Stanford Cancer Center, then walked through one of the most practical topics a NET patient can navigate: how to understand and evaluate clinical trials. From how trials are structured to what questions to ask your care team, this session was designed to help patients feel more empowered, not overwhelmed, when considering their options. 10:10 AM Welcome and Announcements 10:10 - 11:00 AM What is Nuclear Medicine and Molecular Imaging?/Radiation Safety Martin Tornai, PhD, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health 11:00 - 11:45 AM How to Understand and Evaluate Clinical Trials George Fisher, MD, PhD, Stanford Cancer Center, Palo Alto, CA Recording of the Morning Session Over Lunch: Innovations in Imaging For those attending in person, lunch was more than a meal. Simon Cherry, PhD, of UC Davis, offered an exclusive mid-day talk, "Seeing is Believing," on the latest imaging innovations and how advances in technology are translating into better, more precise patient care. The Afternoon: All of This, So We Can Live The afternoon opened in the most meaningful way possible: with a patient story. NCF community member Brenna Bash took the stage and set the tone for everything that followed. Her story was a reminder that behind every data point, every clinical breakthrough, and every hour spent in a treatment chair is a person who wants to be present for their life. Not just to survive, but to truly live. That spirit carried through every session that followed. 1:20 PM Neuroendocrine Tumor Overview George Fisher, MD, PhD · Stanford University 1:40 PM Meet the Author poster presentations Lisa Bodei, MD, PhD (MSK) & Frank Lin, MD (NCI) 2:00 PM Optimizing your health for your NET journey Eric Liu, MD · Healing NET Foundation 2:40 PM The role of interventional radiology Gabriel Fine, MD · City of Hope Cancer Center 3:00 to 3:50 PM Theranostics: where we are now and where we're going Lisa Bodei, MD, PhD · Erik Mittra, MD, PhD · Richard Baum, MD, PhD Dr. Eric Liu's session on optimizing health for the NET journey brought this theme into sharpest focus, addressing not just treatment but the whole person navigating it. And the theranostics sessions with Drs. Bodei, Mittra, and Baum made clear how rapidly the field is expanding, with options growing for patients whose tumors express somatostatin receptors and, crucially, for those in G3 NET and beyond who have historically had fewer paths forward. Professor Richard Baum brought the afternoon to a close with words that felt like the perfect summation of everything the day had stood for. Recording of the Afternoon Session "Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less." - Marie Curie, as shared by Prof. Richard Baum The Experts Who Made It Possible Richard Baum, MD Curanosticum Wiesbaden, Germany Lisa Bodei, MD, PhD Memorial Sloan Kettering, NY Gabriel Fine, MD City of Hope, Duarte, CA George Fisher, MD, PhD Stanford Cancer Center Eric Liu, MD Healing NET Foundation Erik Mittra, MD, PhD Oregon Health & Science University More Than Education: A Community What makes events like this special isn't just the science. It's the moment a patient realizes they're not navigating this alone, that there's a room full of people who understand the fear, the hope, and the determination it takes to live with a neuroendocrine cancer diagnosis. The in-person networking reception that closed the day gave attendees space to connect, share, and simply be with others who truly get it. The NCF Team, including Lisa Yen, Heather Davis & Mary Donlevy Thanks to Josh Mailman, NorCal CarciNET, the Society of Nuclear Medicine and Molecular Imaging, and to every speaker who gave their expertise and their time. Thank you to Brenna for her courage in sharing her story. We do all of this because patients deserve to live, and to live well. Stay connected with NCF To watch more educational webinars on a variety of topics, visit our YouTube Channel and explore more resources at NCF.net. Our support line, virtual support groups, and NETCONNECT peer-to-peer program are here for you year-round. THANKS TO NCF SPONSORS

We thank Jaydira Del Rivero, MD, for reviewing this blog post. In March 2025, the U.S. FDA approved a new treatment option for neuroendocrine tumors: cabozantinib. (Cabometyx® is the brand name of this medication, manufactured by Exelixis.) Although this pill has long been used to treat other cancers, it is now approved for patients 12 years and older with previously treated, advanced neuroendocrine tumors. 👉 For background on the CABINET trial and what the trial data showed, read our March 26, 2025 blogpost: Positive Results of the CABINET Trial Show Cabozantinib as a New, Effective Treatment in Advanced Neuroendocrine Tumors and watch our Nov 2025 Interview with Dr. Aman Chauhan Update on Cabozantinib. Cabozantinib is an oral, non-chemotherapy pill from the category of medications called a VEGF tyrosine kinase inhibitor (or TKI). It's a targeted therapy that works to inhibit the growth of blood vessels in the tumors and also can work to slow growth. As more patients begin taking cabozantinib, it has become one of the most frequently discussed topics in our weekly support groups. Many people want to know what to expect, how to take the medication correctly, how it may affect daily life, and what practical steps can help them feel more prepared. Below are tips and tricks gathered from firsthand patient and caregiver experience, including NET caregiver Lisa Yen’s “show and tell,” which offers practical tools she and her husband found helpful when preparing for Cabozantinib. Important: Always consult your healthcare team with any questions or concerns about your care. This information is provided solely for educational purposes to support and inform patients and caregivers. It is not intended to substitute for professional medical advice, clinical judgment, diagnosis, or treatment, nor should it replace direct discussions with your healthcare providers. Download the transcript of this video >>> Key Resources and Helpful Items 1. Order the free Cabometyx® Patient Care Kit and join the Be Connected support program The Cabometyx Patient Care Kit is available directly from the manufacturer, Exelixis and includes: Samples to help manage common side effects Educational materials on cabozantinib A treatment journal to track symptoms, blood pressure readings, and communication with your care team A patient handbook with tips and guidance Many patients find this kit reassuring and helpful to have on hand. 2. Listen to Podcast Episode 50: Spotlight on Pharmacists Pharmacists, especially oncology pharmacists, play a key role in helping patients navigate targeted oral therapies. This episode discusses: How to take cabozantinib safely What to avoid Common drug interactions Ways to manage side effects How pharmacists can support you throughout treatment Udderly Smooth® cream Cabozantinib can cause hand foot syndrome, a side effect that may lead to redness, sensitivity, or discomfort in the hands and feet. Patients often find that the over-the-counter Udderly Smooth cream: Helps moisturize dry or irritated skin Is non-greasy Works well when applied at bedtime Blood Pressure Cuff Cabozantinib can increase blood pressure, so monitoring at home is essential. Tips: Check your blood pressure at the same time each day, preferably in the morning Record each reading so your care team can identify trends Know the parameters for when to call your doctor. Your doctor may prescribe medications to manage your blood pressure. Ask your doctor who you should be reporting your blood pressure readings to and who will be the one to prescribe and manage high blood pressure. 5. Helpful Items for Nausea or Altered Taste Some people taking cabozantinib experience nausea or altered taste. The following tips and tools may help manage these symptoms: Lemon or lime Some people find adding a few drops of lemon or lime to their water helps with altered taste or nausea. Herbal inhaler Some patients find that inhaling soothing herbal scents can help ease nausea. Lozenges Products such as Organic Morning Ease by Traditional Medicinals or Tummy Drops peppermint lozenges may help soothe nausea. Nonmetal utensils Using bamboo or other non-metal utensils may help reduce metallic taste during meals, if this is one of your symptoms. Biotène® oral rinse Some patients experience dry mouth, mouth sores, or changes in taste. An alcohol-free over-the-counter rinse like Biotène can soothe mouth dryness, reduce discomfort, and make eating easier when used before meals. If nausea persists, ask your doctor about prescription anti-nausea medications. Your care team can help determine what is appropriate for you. The following guidance is adapted from patient education materials provided by the manufacturer of cabozantinib (Exelixis, maker of the FDA-approved drug Cabometyx®). For more information, visit: https://www.cabometyx.com/resources Always discuss any questions or concerns with your healthcare team before making changes or trying new strategies. How to Take Cabozantinib Swallow tablets whole. Do not crush, chew, or dissolve them Take on an empty stomach: one hour before eating or two hours after eating Take it at the same time each day. Any time of day is fine as long as it is consistent If you miss a dose and more than 12 hours have passed, skip it and take the next scheduled dose Food and Drug Interactions While taking cabozantinib, do not eat or drink grapefruit, grapefruit juice, or grapefruit-containing products because they can affect how the medication is absorbed. Inform your health care provider of all medications you take, including prescription medications, over-the-counter products, vitamins, and herbal supplements. This helps your care team identify any possible interactions and keep you safe during treatment. Monitoring Symptoms Track symptoms such as: Mouth sores Changes in taste Dry mouth Hoarseness or voice changes Skin and hair changes, such as changes in color, dry skin, rash Fatigue Digestive issues such as nausea or diarrhea Daily tracking helps your provider decide whether dose adjustments, side effect management strategies, or treatment breaks are needed. Communication Is Key Frequent communication with your healthcare team, supported by your journal or tracking system, helps ensure the treatment is safe, tolerable, and effective. Final Thoughts Starting a new medication can bring uncertainty, especially when it affects daily routines. These tips and tools have helped many people feel more prepared and empowered as they begin Cabozantinib. For more information and resources, explore our video library and podcasts. You are not alone. We are here to support you. THANKS TO NCF SPONSORS

WEEKLY Virtual NET Support Group Meetings No meeting Wednesday, July 1st. Next meeting: July 8th 12:00 - 1:30 PM Pacific Register We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, Neuroendocrine Tumor (NET). Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to NET patients and caregivers. Join us via Zoom every Wednesday at 12 -1:30 PM Pacific Time. Before the live support meeting, please be sure to download Zoom on your preferred device: zoom.us/download Click here to watch a tutorial on how to download and join Zoom. *Please note all Zoom meeting details will be emailed to you within 24 hours of your registration. Questions? Email events@ncf.net . *Limited spots available. NET Support Group Registratin Register THANKS TO OUR SUPPORTERS

Connect with the Neuroendocrine Cancer Foundation for vital resources and a supportive community tailored for NET patients and their caregivers. Watch Podcast Blog Resources by Topic LATEST FROM NCF New Podcast - "Spotlight on Surgical Oncology" with Dr. Concors New - "Luncheon With The Experts" with Dr. Del Rivero Blog Pos t - "Continuing A 60-Year Legacy" "2025 Highlights in Neuroendocrine Cancer" New Blogpost - "The Email That Changed Everything" - Dusty Hurley New Educational Event - "The Latest on Immunotherapy for Neuroendocrine Cancer" with Dr. Aman Chauhan New Podcast Episode - "Spotlight on Pharmacists" with Amanda Cass, PharmD, BCPS, BCOP Watch "2025 Updates in NET" with Dr. Aman Chauhan Watch "The Latest in High-Grade Neuroendocrine Carcinoma (NEC)" with Dr. Aman Chauhan Watch "The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal" Watch "Bridging Inequities in Neuroendocrine Cancer Care: A Conversation" with Dr. Udhayvir Grewal Clinical Trial Update - Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms SIGN UP FOR EMAIL Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE NCF EVENTS 2026 NCF Annual Conference June 20, 2026 Virtual Watch Team Craig Fundraiser July 1, 2026 In-Person Buy Tickets or Sponsor Visit our events page for more information >>> MAKE A DIFFERENCE Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide WATCH 500+ Videos on Various Topics 2025 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn How You Can Share Your Story RECENT EDUCATIONAL EVENTS FOR PATIENTS Play Video Play Video 01:33:06 Novel Targeted Therapies in Neuroendocrine Cancers • 2026 NCF Event • Mar 9, 2026 Some Topics Covered: Neuroendocrine, NET, NEC, High-grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. Visit the event page at https://www.ncf.net/events/mar2026 Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 01:31:30 The Latest on Immunotherapy for Neuroendocrine Cancer • 2025 NCF Event • Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is the national principal investigator on several investigator-initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Visit https://www.ncf.net/events/dec2025 for more information. Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. Play Video Play Video 01:30:51 "Understanding Treatments for NETs and Rationale for Sequencing of Therapy" • Dr. Wolin • Apr 1, 25 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. Learn more at https://www.ncf.net/events/apr2025 LATEST PODCAST EPISODES LISTEN LISTEN LISTEN LISTEN RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine cancer experts answer the top 10 FAQs on various topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers ABOUT THE NEUROENDOCRINE CANCER FOUNDATION Why Our Work Matters The Neuroendocrine Cancer Foundation (NCF) exists to ensure no one faces neuroendocrine cancer alone. We support patients, caregivers, and clinicians through education, connection, and compassionate resources. Educate Educational Events Luncheon With The Experts w/Live Q&A In-Person Patient & Caregiver Events Online Video Library (YouTube & Web) Resource Library on 25 Topics Podcast Spanish Resources Support Support Line Resources for Newly Diagnosed Support Groups Health & Wellness Retreat Wellness Coaching Connect NETCONNECT Peer-to-Peer Program NET VITALS NET INTRO Inform Clinical Trials Guide Amplify Patient Voice Neuroendocrine cancer (also known as NET, neuroendocrine tumor, neuroendocrine neoplasm, carcinoid, or neuroendocrine carcinoma) is a rare/uncommon and complex disease. 8 in 100,000 people in the U.S. are diagnosed each year Symptoms vary widely and are often misunderstood Diagnosis can take several years Many patients do not meet someone else living with neuroendocrine cancer until they find NCF Patients often struggle to find specialists, up-to-date treatment guidance, and emotional support. NCF fills those gaps by offering what patients need most: credible education, expert access, and a community that understands. NCF provides these life-changing resources — ensuring patients and families receive guidance when it matters most. I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient

Neuroendocrine Cancer Foundation Upcoming Patient & Caregiver Events 2026 Annual Patient Conference June 20, 2026, 7:00 AM - 1 PM Pacific Join the Virtual 2026 Neuroendocrine Cancer Patient Conference, featuring 19 leading NET experts and the theme Navigating a Changing Neuroendocrine Cancer Landscape. Learn about key topics in NET care, hear patient stories, and get your questions answered during a live Q&A. Watch Team Craig Fundraiser Benefitting Neuroendocrine Cancer Foundation Denver, Colorado July 1, 2026, 6 - 10 PM Mountain Join Team Craig for a casual fundraiser at a local brewery in support of the Neuroendocrine Cancer Foundation. This relaxed event brings together patients, caregivers, advocates, friends and supporters for an event of connection, conversation, and awareness-building for the neuroendocrine cancer community. Come enjoy great company, live music, refreshments, food, and community while supporting efforts to advance education, support, and patient resources for those impacted by neuroendocrine cancer. Buy Tickets or Sponsor Neuroendocrine Cancer Patient Support Group Weekly on Wednesdays May: 6, 13, 20, 27, 2026 June: 3, 10, 17, 24, 2026 We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, neuroendocrine cancer. Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to neuroendocrine cancer patients and caregivers. Register Neuroendocrine Cancer Caregiver Support Group Typically on the Last Saturday of the Month Dates: Feb 28, 2026 Mar 28, 2026 Apr 25, 2026 May 30, 2026 Jun 27, 2026 Jul 25, 2026 Aug 29, 2026 Sep 26, 2026 Oct 24, 2026 Nov 21, 2026 Dec 19, 2026 Neuroendocrine Cancer Foundation's Monthly NET Caregiver-Only support group is a virtual space to come together for support, connection and community with other care partners who support, or have supported, those with Neuroendocrine Cancer. Unlike our Weekly Wednesday Support Group for Caregivers & Patients that focuses on medical aspects of NETs, this group focuses on the unique experiences and psycho-social concerns of caregivers. *OPEN TO NET CAREGIVERS ONLY. Register Click here for recent events